Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, ritlecitinib 50-mg showed clinically meaningful efficacy, with improvements in the Severity of Alopecia Tool score observed in patients with alopecia areata over a 3-year period, demonstrating long-term benefit in both clinician- and patient-reported outcomes.

This case study describes a 9-year-old boy with monilethrix and associated abnormalities, suggesting a new, severe autosomal recessive variant termed "monilethrix syndrome.

In this study, a case of alopecia areata was successfully treated using Ayurvedic medicine, highlighting its potential as an alternative to corticosteroids and immunosuppressants, which can have serious adverse effects with prolonged use.

This review discusses valproate-associated hair abnormalities, describing their common and benign nature, and outlines management strategies, though new clinical results are not provided.

In this study, photobiomodulation therapy applied twice weekly for 12 weeks significantly improved hair regrowth and quality of life in alopecia areata patients, with no noted side effects.

This study reported that diffuse lichen planopilaris significantly impairs quality of life in Moroccan patients, with trichodynia and hair quality changes most affecting daily functioning and leisure activities.

Ritlecitinib helps regrow hair in alopecia areata and is safe for long-term use.

This study found that treatment with baricitinib 4 mg over 52 weeks led to clinically meaningful regrowth of eyebrows and eyelashes in patients with alopecia areata, even without complete scalp hair regrowth.

This article presents a unique case of post-partum panhypopituitarism and autoimmune conditions in a 37-year-old woman from Africa, emphasizing the need for early diagnosis and treatment to improve outcomes in similar settings.

This study found that using calcipotriene and betamethasone dipropionate cream in a real-world setting significantly improved clinical outcomes and patient quality of life for adults with mild-to-moderate scalp psoriasis, especially among those with higher adherence, demonstrating high treatment satisfaction.

This case study suggests that early or significant alopecia in young adults may warrant investigation for underlying congenital conditions like trichorhinophalangeal syndrome.

This study found that ritlecitinib was well tolerated in children aged 6 to under 12 years with severe alopecia areata, with ongoing trials examining its efficacy and safety over a 24-week period and in long-term use up to 36 months.

In this case report, a 13-year-old girl with Pitt-Hopkins syndrome developed hair curling after starting the antiepileptic drug perampanel, which had not been previously reported as a side effect.

This report describes a 7-year-old girl with monilethrix who showed significant improvement while on acitretin treatment, but symptoms returned after stopping the medication.

In this case study, combination therapy with dapsone and isotretinoin significantly improved perifolliculitis capitis abscedens et suffodiens, with the patient remaining symptom-free for six months on reduced medication.

This study indicates that reduced activity of the matriptase-prostasin proteolytic cascade is likely the cause of human autosomal recessive ichthyosis with hypotrichosis, as demonstrated using a novel mouse model.

This report describes a case of twins with alopecia areata totalis who did not respond to corticosteroids but showed significant hair growth with platelet rich plasma injections, suggesting PRP's potential as an alternative treatment.

This study found that RSL4 in Arabidopsis thaliana regulates genes necessary for root hair elongation by controlling proteins involved in cell signaling, cell wall modification, and secretion.

Platelet-rich plasma treatment for hair loss may improve patients' quality of life.

In this randomized controlled trial, researchers observed that topical clobetasol propionate 0.05% was significantly more effective than topical tacrolimus 0.1% for treating alopecia areata, with a higher treatment success rate of 74.2% versus 45.2%, suggesting clobetasol as a preferred first-line topical therapy.

In this study, ritlecitinib was generally well tolerated in pediatric alopecia areata patients aged 6 to <12 years, with no severe or serious adverse events reported, and the drug's pharmacokinetic parameters were successfully characterized.

This study observed that patients with AA showed a high willingness to trade off lifespan for better disease-specific quality of life, indicating a significant disease burden.

Fear of hair-related issues causes significant mental distress, especially in high-stress women.

This article defines body dysmorphic disorder as excessive concern over perceived physical defects that cause distress and affect social or functional activities, but it reports no new results.

This report highlights that oral Janus kinase inhibitors, including baricitinib, ritlecitinib, deuruxolitinib, and brepocitinib, show promise for treating alopecia areata by promoting substantial hair regrowth with mild-to-moderate side effects, positioning them as a favorable alternative to corticosteroids.

In this study, the researchers reported that baricitinib improved hair loss in a real-world setting for Japanese adults with alopecia areata, with a 64.7% success rate at 60 weeks, though prolonged episodes reduced efficacy. Common side effects were acne and mildly decreased renal function.

This study found that men with common male pattern baldness received less favorable initial social perceptions, including lower ratings of physical attractiveness, than their nonbalding counterparts.

This study reported dramatic improvements in five collodion baby patients with lamellar ichthyosis treated with oral retinoic acid, noting hair loss as the sole adverse effect, emphasizing the treatment's promising efficacy for physicians.

This narrative highlights a study underscoring that vitiligo and alopecia areata are complex autoimmune conditions, often misclassified as cosmetic, which can hinder patients' access to necessary treatments despite their profound impact on quality of life and associated comorbidities.